Skip to main content
. 2022 Nov 1;10(11):2770. doi: 10.3390/biomedicines10112770

Table 2.

Comparison between the three studied groups according to different parameters.

Group I (n = 60) Group II (n = 60) Group III (n = 60) Test of Significance p
A2M-AS1
Median (Min–Max) 1.75 (0.58–2.80) 1.65 (0.20–4.78) 0.44 (0.02–1.0) H = 100.629 * <0.001 *
Significance between Groups p1 = 0.368, p2 < 0.001 *, p3 < 0.001 *
FLVCR1
Median (Min–Max) 1.38 (0.08–3.83) 0.94 (0.12–4.56) 0.48 (0.01–11.25) H = 24.269 * <0.001 *
Significance between Groups p1 = 0.092, p2 < 0.001 *, p3 = 0.002 *
DBH-AS1
Median (Min–Max) 2.45 (0.01–7.62) 5.85 (0.19–11.0) 14.58 (0.25–51.0) H = 68.041 * <0.001 *
Significance between Groups p1 < 0.001 *, p2 < 0.001 *, p3 < 0.001 *
FLVCR1-DT
Median (Min–Max) 0.70 (0.30–1.0) 7.45 (2.40–11.0) 12.70 (2.0–77.0) H = 131.159 * <0.001 *
Significance between Groups p1 < 0.001 *, p2 < 0.001 *, p3 = 0.001 *
NCBP2AS2-1
Median (Min–Max) 0.45 (0.13–1.10) 2.81 (1.51–3.81) 8.98 (2.13–45.77) H = 151.736 * <0.001 *
Significance between Groups p1 < 0.001 *, p2 < 0.001 *, p3 < 0.001 *
CO-RADS
Median (Min–Max) 2.0 (1.0–2.0) 3.0 (3.0–5.0) U = 0.0 * <0.001 *

SD: Standard deviation; F: F for ANOVA test, pairwise comparison between two groups were performed using the post hoc test (Tukey); H: H for the Kruskal–Wallis test, pairwise comparison between two groups were performed using the post hoc test (Dunn’s for multiple comparisons test); p: p-value for comparing the studied groups; p1: p-value for the comparison of Group I and Group II; p2: p-value for the comparison of Group I and Group III; p3: p-value for the comparison of Group II and Group III. *: Statistically significant at p ≤ 0.05. Group I: Control group; Group II: Moderate COVID-19 infection; Group III: Severe COVID-19 infection.